The Phase III clinical trial of the novel TYK2 inhibitor ICP-488 for the treatment of psoriasis has completed patient enrollment.

On February 2nd, Novartis announced that the Phase III clinical trial of the company's independently developed novel TYK2 inhibitor ICP-488 for the treatment of psoriasis has completed patient enrollment, with a total of 383 patients enrolled. This milestone signifies a significant clinical advancement in the treatment of psoriasis with ICP-488, offering new oral treatment options for patients with psoriasis. This clinical trial is a multicenter, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of ICP-488 monotherapy in adult patients with severe plaque psoriasis.